Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Günaj Rakipovski"'
Autor:
Günaj Rakipovski, PhD, Bidda Rolin, DVM, Jane Nøhr, PhD, Ib Klewe, PhD, Klaus S. Frederiksen, PhD, Robert Augustin, PhD, Jacob Hecksher-Sørensen, PhD, Camilla Ingvorsen, PhD, Joseph Polex-Wolf, PhD, Lotte Bjerre Knudsen, DMSc
Publikováno v:
JACC: Basic to Translational Science, Vol 3, Iss 6, Pp 844-857 (2018)
Summary: The glucagon-like peptide-1 receptor agonists (GLP-1RAs) liraglutide and semaglutide reduce cardiovascular risk in type 2 diabetes patients. The mode of action is suggested to occur through modified atherosclerotic progression. In this study
Externí odkaz:
https://doaj.org/article/2d522d42a8bd4b7390f2d85e3fee3cac
Autor:
Julie Hviid Klaebel, Günaj Rakipovski, Birgitte Andersen, Jens Lykkesfeldt, Pernille Tveden-Nyborg
Publikováno v:
Antioxidants, Vol 9, Iss 9, p 808 (2020)
Despite the lack of effective pharmacotherapy against nonalcoholic steatohepatitis (NASH) and liver fibrosis, vitamin E (vitE) supplementation and lifestyle modifications are recommended for the management of NASH due to promising clinical results. W
Externí odkaz:
https://doaj.org/article/5595e4f5a21040569500a378df4604fc
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0147412 (2016)
Pulsatile hyperglycaemia resulting in oxidative stress may play an important role in the development of macrovascular complications. We investigated the effects of sustained vs. pulsatile hyperglycaemia in insulin resistant rats on markers of oxidati
Externí odkaz:
https://doaj.org/article/eb75006ed77f4da387d1d72c7ece2c89
Autor:
Mariette Lengquist, Mathilde Frederikke Bjørn Bonde, G. Kees Hovingh, Heidi Engslev Lund, Bidda Rolin, Stefan Zahn, Michael Nyberg, Karin Hultman, Lars Maegdefessel, Valentina Manfè, Pernille Gry Wulff-Larsen, Karin Conde-Knape, Ulf Hedin, Djordje Djordjevic, Rikke Kaae Kirk, Ljubica Perisic Matic, Niels Blume, Günaj Rakipovski, Maj Petersen, Natasha Barascuk
Publikováno v:
Atherosclerosis, 314, 1-9. Elsevier Ireland Ltd
Background and aims Clinical interventions targeting nonlipid risk factors are needed given the high residual risk of atherothrombotic events despite effective control of dyslipidemia. Dickkopf-1 (DKK1) plays a lipid-independent role in vascular path
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0efec751ef9e7504d11804548f133081
https://doi.org/10.1016/j.atherosclerosis.2020.10.001
https://doi.org/10.1016/j.atherosclerosis.2020.10.001
Autor:
Katrine Dahl Bjørnholm, Pernille Tveden-Nyborg, Gro Klitgaard Povlsen, Gry Freja Skovsted, Anne Mitgaard‐Thomsen, Jens Lykkesfeldt, Günaj Rakipovski
Publikováno v:
Basic & Clinical Pharmacology & Toxicology. 128:103-114
Recent clinical intervention studies have shown that the GLP1 analogue liraglutide lowers cardiovascular risk, but the underlying mechanism has not yet been fully elucidated. This study investigated the effects of liraglutide on endothelial function
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f58cdf552273e270ff773de5dca72a96
https://doi.org/10.1111/bcpt.13486
https://doi.org/10.1111/bcpt.13486
Autor:
Pernille Tveden-Nyborg, Gro Klitgaard Povlsen, Charles Pyke, Günaj Rakipovski, Katrine Dahl Bjørnholm, Gry Freja Skovsted, Jens Lykkesfeldt, Maria Elm Ougaard
Publikováno v:
The Journal of endocrinology. 248(3)
The glucagon-like peptide-1 receptor (GLP1R) is expressed in the renal vasculature and known to be downregulated under hypertensive conditions in rats and humans. However, little is known about the regulation in other types of renal pathology involvi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84d308ac127da5cd609387299ba8aa20
https://pubmed.ncbi.nlm.nih.gov/33449915
https://pubmed.ncbi.nlm.nih.gov/33449915
Publikováno v:
Current opinion in lipidology, 31(6), 340-346. Lippincott Williams and Wilkins
Purpose of review Despite the wide use of statins and other LDL-cholesterol (LDL-C)-lowering therapies, atherosclerotic cardiovascular disease remains an important cause of mortality and morbidity. Here, we discuss efficacy, side effects and convenie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15763474e2a48ab7ff31b113d2c275e0
https://pubmed.ncbi.nlm.nih.gov/33060383
https://pubmed.ncbi.nlm.nih.gov/33060383
Autor:
Robert Augustin, Lotte Bjerre Knudsen, Klaus Stensgaard Frederiksen, Jane Nøhr, Ib Klewe, Joseph Polex-Wolf, Günaj Rakipovski, Bidda Rolin, Camilla Ingvorsen, Jacob Hecksher-Sørensen
Publikováno v:
JACC: Basic to Translational Science
JACC: Basic to Translational Science, Vol 3, Iss 6, Pp 844-857 (2018)
JACC: Basic to Translational Science, Vol 3, Iss 6, Pp 844-857 (2018)
Visual Abstract
Highlights • The GLP-1RAs liraglutide and semaglutide reduce cardiovascular risk in type 2 diabetes patients. • In ApoE−/− mice and LDLr−/− mice, liraglutide and semaglutide treatment significantly attenuated plaque l
Highlights • The GLP-1RAs liraglutide and semaglutide reduce cardiovascular risk in type 2 diabetes patients. • In ApoE−/− mice and LDLr−/− mice, liraglutide and semaglutide treatment significantly attenuated plaque l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a2285f7b2f401e31c02827d624d53aa
http://europepmc.org/articles/PMC6314963
http://europepmc.org/articles/PMC6314963
Autor:
Petr, Zouhar, Günaj, Rakipovski, Muhammad Hamza, Bokhari, Oliver, Busby, Johan F, Paulsson, Kilian W, Conde-Frieboes, Johannes J, Fels, Kirsten, Raun, Birgitte, Andersen, Barbara, Cannon, Jan, Nedergaard
Publikováno v:
American Journal of Physiology-Endocrinology and Metabolism
The possibility to use leptin therapeutically for lowering glucose levels in patients with type 1 diabetes has attracted interest. However, earlier animal models of type 1 diabetes are severely catabolic with very low endogenous leptin levels, unlike
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::63eabe2f880be82adf1e7bb2d9cc7e8d
https://pubmed.ncbi.nlm.nih.gov/31743040
https://pubmed.ncbi.nlm.nih.gov/31743040
Publikováno v:
Current Diabetes Reviews
Glucagon-like peptide-1 (GLP-1) has shown to influence the oxidative stress status in a number of in vitro, in vivo and clinical studies. Well-known effects of GLP-1 including better glycemic control, decreased food intake, increased insulin release
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d7688fb01182b92aa3dc27762a33100
https://doi.org/10.2174/1573399812666150918150608
https://doi.org/10.2174/1573399812666150918150608